Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | GAA | P10253 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21722656 | 0.78 | GRIN2D (0.41) | MAPTGAAKDM4EBAZ2BSMN1; SMN2 | |
| SCHEMBL29575133 | 0.78 | GRIN2D (0.41) | MAPTGAAKDM4EBAZ2BSMN1; SMN2 | |
| SCHEMBL8669474 | 0.74 | CA1 (0.41) | MAPTGAAKDM4ECA1CA2 | |
| SCHEMBL2320088 | 0.74 | MAPT (0.43) | MAPTGAAKDM4ESMN1; SMN2HTT | |
| SCHEMBL5582446 | 0.74 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL8669479 | 0.71 | KDM4E (0.33) | MAPTGAAKDM4E | |
| SCHEMBL29207333 | 0.70 | MAPT (0.40) | MAPTGAAKDM4ESMN1; SMN2HTT | |
| SCHEMBL8669483 | 0.70 | KDM4E (0.33) | MAPTGAAKDM4ESMN1; SMN2 | |
| SCHEMBL9093677 | 0.70 | MAPT (0.34) | MAPTGAAKDM4ESMN1; SMN2 | |
| SCHEMBL14415151 | 0.70 | SMN1; SMN2 (0.50) | MAPTGAAKDM4ESMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070087346-A1 | Orthogonal gene switches | CILIBERTO GENNARO | 2007-04-19 | — | — | US | disclosed |
| US-20070087346-A1 | Orthogonal gene switches | CILIBERTO GENNARO | 2007-04-19 | — | — | US | disclosed |
| US-20070087346-A1 | Orthogonal gene switches | CILIBERTO GENNARO | 2007-04-19 | — | — | US | disclosed |
| EP-1680447-A2 | ORTHOGONAL GENE SWITCHES | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2006-07-19 | — | — | EP | disclosed |
| WO-2005040212-A2 | ORTHOGONAL GENE SWITCHES | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070087346-A1 | Orthogonal gene switches | TCF12, JUN, TCF7 | MAPT 4167/4885GAA 3308/4885KDM4E 2706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.